<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765452</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_CLO_401</org_study_id>
    <nct_id>NCT01765452</nct_id>
  </id_info>
  <brief_title>Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone</brief_title>
  <official_title>Multi-center, Randomized, Open Study for Comparison of Efficacy and Safety of Plavix With Astrix and Closone in Patients With Post-Percutaneous Coronary Artery Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Aim of this study is to prove non-inferiority of Closone to the Combination treatment of
      Plavix with Astrix.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baselinine in P2Y12% inhibition at week 8</measure>
    <time_frame>Baseline, week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PRU, ARU at week 8</measure>
    <time_frame>Baseline, week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Closone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg/100mg per day, 8weeks, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plavix with Astrix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75mg per day, 8weeks, PO 100mg per day, 8weeks, PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Closone</intervention_name>
    <description>75mg/100mg, 8weeks, PO</description>
    <arm_group_label>Closone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plavix with Astrix</intervention_name>
    <description>75mg, 100mg a day, 8weeks, PO</description>
    <arm_group_label>Plavix with Astrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects under a stable condition after Post-Percutaneous Coronary Artery Intervention
             over three months

          -  20~86 years old

          -  Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          -  Subject who did not undergo or failed Drug-Stent Implantation

          -  Subjects who took an anti-coagulant, anti-thrombotic regularlly( â‰¥ 2weeks in a month)
             before the study, or plan to have continuous treatment during the study(Except Aspirin
             alone or combination of Aspirin and Clopidogrel)

          -  Subjects with a history of substance or alchol abuse

          -  Subjects with a history of hypersensitivity to Clopidogrel, Aspirin or other NSAIDS

          -  Subjects having Aspirin or other NSAIDs-induced Asthma or history

          -  Subjects with Severe hepatopathy(AST and ALT &gt; 5 times the upper limit of normal)

          -  Subjects with Severe nephropathy(Cr &gt; 3 times the upper limit of normal)

          -  Subjects with hemorrhage like gastric ulcer, intracranial hemorrhage etc.

          -  Subjects with high risk of hemorrhage like blood coagulation disorders, uncontrolled
             severe hypertension, active bleeding, history of severe bleeding

          -  subjects who are pregnant, breastfeeding

          -  Subjects not using medically acceptable birth control

          -  Subjects who are unsuitable to take the Investigational product due to a
             medical/mental condition

          -  Subjects inherently having Galactose malobsorption, Lactase deficiency or
             Glucose-Galactose malobsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje university haeundae paik hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin university gospel hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan national university hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk national university hospital</name>
      <address>
        <city>Chungbuk</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

